Dilated Cardiomyopathy Clinical Trials
5 recruiting trials for Dilated Cardiomyopathy. Eligibility criteria explained in plain English.
TrialFinderData lists 5 Dilated Cardiomyopathy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 is the largest group at 50% (1 studies); the largest phase groups are Phase 1: 1, Phase 3: 1.
Research is led by Indiana University (1), Centro Medico Teknon (1), Emory University (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Allogeneic Neonatal mesenchymal stromal cells (nMSCs) (biological, 1 trial), followed by Bromocriptine mesylate plus standard GDMT.
Track Dilated Cardiomyopathy trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Pediatric Cardiomyopathy Mutation Analysis
The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder. This...
Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy
Risk stratification for sudden cardiac death (SCD) in patients with non-ischemic cardiomyopathy (NICM) remains suboptimal. Although current guidelines rely on severe left...
A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult...
This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy. The purpose of...
Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
Dilated cardiomyopathy (DCM) is a condition associated with left and /or right ventricular (LV) dilatation and systolic dysfunction without coronary artery disease or abnormal...
Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation
The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus on microRNAs (miRNAs) and...
Explore Other Conditions
Frequently Asked Questions
There are currently 5 clinical trials for Dilated Cardiomyopathy, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Dilated Cardiomyopathy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Dilated Cardiomyopathy, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.